Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 12/20 | 0.47 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.45 |
| ▸ | EGFR | P00533 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.40 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.40 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.39 |
| ▸ | TYK2 | P29597 | 1/20 | 0.39 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.39 |
| ▸ | SRPK1 | Q96SB4 | 1/20 | 0.39 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.39 |
| ▸ | MMP13 | P45452 | 1/20 | 0.38 |
| ▸ | BRAF | P15056 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.37 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13472364 | 0.90 | KDM4D (0.57) | KMOKDM4DEGFR | |
| SCHEMBL13472375 | 0.86 | KMO (0.47) | KMOKDM4D | |
| SCHEMBL17383767 | 0.85 | EGFR (0.43) | KDM4DEGFRNPSR1MAP4K4TYK2 | |
| SCHEMBL13472402 | 0.82 | KMO (0.43) | KMOKDM4DCLK4 | |
| SCHEMBL17383191 | 0.82 | EGFR (0.45) | KDM4DEGFRNPSR1CLK4MMP13 | |
| SCHEMBL13472374 | 0.82 | DNM2 (0.52) | KMOKDM4DEGFRCSNK2A2CSNK2B | |
| SCHEMBL13472373 | 0.81 | DNM2 (0.55) | KMOEGFRCSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL13472414 | 0.81 | HCAR3 (0.54) | KMOCLK4 | |
| SCHEMBL13472590 | 0.81 | CYP1A2 (0.55) | KMOKDM4DCLK4 | |
| SCHEMBL13472370 | 0.81 | KMO (0.48) | KMOEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3231798-B1 | THIAZOLE INTERMEDIATES USEFUL IN THE PREPARATION OF RAF KINASE INHIBITORS | SUNESIS PHARMACEUTICALS INC (US) | 2019-10-09 | — | — | EP | disclosed |
| US-9920048-B2 | Substituted pyrimidines for inhibiting Raf kinase activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2018-03-20 | — | — | US | disclosed |
| US-9920048-B2 | Substituted pyrimidines for inhibiting Raf kinase activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2018-03-20 | — | — | US | disclosed |
| EP-3231798-A1 | THIAZOLE INTERMEDIATES USEFUL IN THE PREPARATION OF RAF KINASE INHIBITORS | Sunesis Pharmaceuticals, Inc. (US) | 2017-10-18 | — | — | EP | disclosed |
| US-20170158686-A1 | Compounds Useful as Raf Kinase Inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-06-08 | — | — | US | disclosed |
| US-20170158686-A1 | Compounds Useful as Raf Kinase Inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-06-08 | — | — | US | disclosed |
| EP-2167489-B1 | PYRIMIDINE DERIVATIVES USEFUL AS RAF KINASE INHIBITORS | SUNESIS PHARMACEUTICALS INC (US) | 2017-05-03 | — | — | EP | disclosed |
| US-9556177-B2 | Substituted 1,3-thiazoles as synthetic intermediates for preparation of Raf kinase inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-01-31 | — | — | US | disclosed |
| US-9556177-B2 | Substituted 1,3-thiazoles as synthetic intermediates for preparation of Raf kinase inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-01-31 | — | — | US | disclosed |
| US-20150080568-A1 | COMPOUNDS USEFUL AS RAF KINASE INHIBITORS | XOMA (US) LLC | 2015-03-19 | — | — | US | disclosed |
| US-20150080568-A1 | COMPOUNDS USEFUL AS RAF KINASE INHIBITORS | XOMA (US) LLC | 2015-03-19 | — | — | US | disclosed |
| US-8802657-B2 | Compounds useful as Raf kinase inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-08-12 | — | — | US | disclosed |
| US-8802657-B2 | Compounds useful as Raf kinase inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-08-12 | — | — | US | disclosed |
| US-20130065858-A1 | COMPOUNDS USEFUL AS RAF KINASE INHIBITORS | SUNESIS PHARMACEUTICALS, INC. (US) | 2013-03-14 | — | — | US | disclosed |
| US-20130065858-A1 | COMPOUNDS USEFUL AS RAF KINASE INHIBITORS | SUNESIS PHARMACEUTICALS, INC. (US) | 2013-03-14 | — | — | US | disclosed |
| US-8293752-B2 | Compounds useful as Raf kinase inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-10-23 | — | — | US | disclosed |
| US-8293752-B2 | Compounds useful as Raf kinase inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-10-23 | — | — | US | disclosed |
| US-20090036419-A1 | COMPOUNDS USEFUL AS RAF KINASE INHIBITORS | SUNESIS PHARMACEUTICALS, INC. (US) | 2009-02-05 | — | — | US | disclosed |
| US-20090036419-A1 | COMPOUNDS USEFUL AS RAF KINASE INHIBITORS | SUNESIS PHARMACEUTICALS, INC. (US) | 2009-02-05 | — | — | US | disclosed |
| WO-2009006389-A2 | PYRIMIDINE DERIVATIVES USEFUL AS RAF KINASE INHIBITORS | SUNESIS PHARMACEUTICALS, INC. (US) | 2009-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036419-A1 | COMPOUNDS USEFUL AS RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | KMO 3678/4885KDM4D 3363/4885EGFR 558/4885 |
| US-20170158686-A1 | Compounds Useful as Raf Kinase Inhibitors | BRAF, RAF1, ARAF | KMO 3678/4885KDM4D 3363/4885EGFR 558/4885 |
| US-20130065858-A1 | COMPOUNDS USEFUL AS RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | KMO 3678/4885KDM4D 3363/4885EGFR 558/4885 |
| US-20150080568-A1 | COMPOUNDS USEFUL AS RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | KMO 3678/4885KDM4D 3363/4885EGFR 558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.